WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100810
Description: Temozolomide, also known as SCH 52365 , MB39831, and RP46161, is a triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system.
MedKoo Cat#: 100810
Chemical Formula: C6H6N6O2
Exact Mass: 194.05522
Molecular Weight: 194.15
Elemental Analysis: C, 37.12; H, 3.11; N, 43.29; O, 16.48
Temozolomide, purity > 98%, is in stock. The same day shipping out after order is received.
Synonym: SCH-52365; SCH52365; SCH 52365; MB39831; MB-39831; MB 39831; RP46161; RP 46161; R-P46161; CCRG81045; TMZ. US brand names: Methazolastone; Temodar. Foreign brand name: Temodal
IUPAC/Chemical Name: 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide.
InChi Key: BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChi Code: InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
SMILES Code: O=C(C1=C(N2C=N1)N=NN(C)C2=O)N
The following data is based on the product molecular weight 194.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013 Apr 30;4:CD007415. doi: 10.1002/14651858.CD007415.pub2. Review. PubMed PMID: 23633341.
2: Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol. 2013 Jun;113(2):163-74. doi: 10.1007/s11060-013-1110-x. Epub 2013 Mar 28. Review. PubMed PMID: 23535992.
3: Hirst TC, Vesterinen HM, Sena ES, Egan KJ, Macleod MR, Whittle IR. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer. 2013 Jan 15;108(1):64-71. doi: 10.1038/bjc.2012.504. Review. PubMed PMID: 23321511; PubMed Central PMCID: PMC3553514.
4: Grant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci. 2013 May;58(5):1415-21. doi: 10.1007/s10620-012-2493-9. Epub 2012 Dec 5. Review. PubMed PMID: 23212393; PubMed Central PMCID: PMC3826911.
5: Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090. doi: 10.1155/2012/831090. Epub 2012 Oct 24. Review. PubMed PMID: 23133490; PubMed Central PMCID: PMC3486128.
6: De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. 2013 Mar;85(3):373-82. doi: 10.1016/j.critrevonc.2012.08.002. Epub 2012 Aug 25. Review. PubMed PMID: 22925496.
7: Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs. 2012 Nov;23(10):1099-106. Review. PubMed PMID: 22850321.
8: Scorsetti M, Alongi F, Clerici E, Navarria P, Simonelli M, Rognone E, Santoro A. Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. Tumori. 2012 May-Jun;98(3):67e-71e. doi: 10.1700/1125.12413. Review. PubMed PMID: 22825521.
9: Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, Durando X. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013 Apr;39(2):125-35. doi: 10.1016/j.ctrv.2012.06.002. Epub 2012 Jul 19. Review. PubMed PMID: 22818211.
10: Jiang G, Li LT, Xin Y, Zhang L, Liu YQ, Zheng JN. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT. Curr Med Chem. 2012;19(23):3886-92. Review. PubMed PMID: 22788764.
According to http://en.wikipedia.org/wiki/Temozolomide, Temozolomide (brand names Temodar and Temodal Schering-Plough Corporation) is an oral alkylating agent which can be used for the treatment of Grade IV astrocytoma -- an aggressive brain tumor, also known as glioblastoma multiforme as well as Melanoma, a form of skin cancer. It is also indicated for Grade III Anaplastic Astrocytoma and not indicated for, but now used to treat oligodendroglioma brain tumors in some countries, replacing the older (and less well-tolerated) PCV (Procarbazine-Lomustine-Vincristine) regimen. The agent was developed by Malcolm Stevens and his team at Aston University in Birmingham, A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). It has been available in the US since August 1999, and in other countries since the early 2000s.
TEMODAR contains temozolomide, an imidazotetrazine derivative. The chemical name of temozolomide is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide. The material is a white to light tan/light pink powder with a molecular formula of C6H6N6O2 and a molecular weight of 194.15. The molecule is stable at acidic pH ( < 5) and labile at pH > 7; hence TEMODAR can be administered orally and intravenously. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.
Temozolomide is available in the United States in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg & 250 mg capsules. Now also available in an IV form for people who can not swallow capsules or who have insurance that does not cover oral cancer agents!